Biosecure compromise could add executive review process for named companies, sources say
Lawmakers are considering a compromise to legislation targeting Chinese life science companies that would add an executive branch review instead of automatically barring biopharma companies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
